Regenxbio (RGNX) Other Operating Expenses (2014 - 2025)

Regenxbio's Other Operating Expenses history runs 12 years deep, the most recent figure standing at -$72.4 million for Q4 2025.

• On a quarterly basis, Other Operating Expenses fell 3466.99% year-over-year to -$72.4 million in Q4 2025; TTM through Dec 2025 was -$134.9 million, a 527.89% decrease from a year earlier, with the FY2025 full-year figure at -$278.3 million, down 982.58% from the prior year.
• Other Operating Expenses fell to -$72.4 million in Q4 2025 per RGNX's latest filing, from $5.8 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $38.0 million in Q1 2022 and bottomed at -$422.8 million in Q4 2022.
• The 5-year median for Other Operating Expenses is $7.9 million (2023), against an average of -$20.1 million.
• Across the five-year window, Other Operating Expenses soared 20008.0% in 2021 and slumped 3466.99% in 2025, its largest moves.
• Year by year, Other Operating Expenses stood at $15.0 million in 2021, then tumbled by 2910.99% to -$422.8 million in 2022, then jumped by 86.33% to -$57.8 million in 2023, then soared by 103.72% to $2.2 million in 2024, then slumped by 3466.99% to -$72.4 million in 2025.
• Per Business Quant, the three latest RGNX Other Operating Expenses figures stand at -$72.4 million (Q4 2025), $5.8 million (Q3 2025), and -$71.7 million (Q2 2025).